-
-
-
-
-
-
-
Elutia secures $15M loan from Avenue Capital for NXT-41x launch
-
-
-
-
-
-
-
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
-
-
-
-
-
-
-
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
-
-
-
-
-
-
-
Elutia reports 49% sequential growth in EluPro revenue for Q2
-
-
-
-
-
-
-
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
-
-
-
-
-
-
-
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™
-
-
-
-
-
-
-
Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025
-
1,188,187 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

